Deal to progress Alzheimer's vaccine

AFFiRiS GmbH has granted GlaxoSmithKline Biologicals S.A. (GSK) exclusive rights to develop and commercialise its Alzheimer's disease vaccine candidates. Two are currently in Phase I clinical development, and others are in preclinical development.

The AFFiRiS AFFiTOPE technology allows the design of proteins with very specific binding characteristics that are ideally suited for the development of vaccines against disease-causing ‘rogue’ human proteins, such as beta-amyloid – central to Alzheimer’s disease pathology.
AFFiRiS GmbH (www.affiris.com) develops peptide-based vaccines to combat Alzheimer’s disease, atherosclerosis and other diseases. The company has established platform technologies and a worldwide patent portfolio covering their vaccine candidates.

20.11.2008

Article • Pros and cons of academic-industry partnerships

Computational pathology: Building bridges between labs and business

Academic-industry partnerships are playing a crucial role in advancing computational pathology. At the Digital Pathology and AI Congress: Europe in London in December, Liron Pantanowitz outlined the…

Early Detection of Invasive Fungal Infections: The β-D-Glucan Test on the LIMUSAVE MT-7500

Invasive fungal infections are silent, fast-moving, and notoriously hard to catch in time. The FUJIFILM Wako β-D-Glucan Test on the LIMUSAVE MT-7500 gives clinical laboratories a quantitative,…

News • Post-injury axon regrowth

Lab-grown model shows ‘irreversible’ spinal cord damage may be reversed

When the spinal cord is damaged, the resulting paralysis is usually considered permanent. Now, a new research approach using lab-grown organoid models suggests that it actually might be reversed.